Compare Commvault Systems Inc (CVLT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Johnson & Johnson — how do they compare? Commvault Systems Inc trades at $157.25 (market cap $6.25B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 98.9× Commvault Systems Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Johnson & Johnson for 129 Days on average.
| CVLT | JNJ | |
|---|---|---|
Market Cap | $6.25B | $618.09B |
Volume | 632,727 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $176.43 | $278.43 |
52-Week Low | $75.18 | $186.00 |
Typical Hold Time | 17 Days | 129 Days |
Enterprise Value | $6.24B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVLT trades at $151.00, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights include achieving AWS Data Competency and expanding FedRAMP High authorized services, reinforcing its enterprise resilience focus.
Outlook remains positive given earnings momentum and strategic partnerships, though high valuation multiples and a projected decline in net profit margin for 2026 present risks. The consensus price target of $156.55 suggests modest upside from current levels, supported by a unanimous lack of sell ratings from analysts.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
